Pfizer and BioNTech said they have submitted their COVID-19 vaccine to the European Medicines Agency for conditional approval.
The companies said this in a statement on Tuesday, aiming to make their drug available in Europe by the end of the year.
The partners, a U.S. pharma giant and a small German biotechnology firm specialising in nascent mRNA technology, said receipt of their application had been confirmed after it was submitted on Monday.
This puts the companies neck and neck with U.S. firm Moderna, which also applied to the EU regulator for the conditional approval of its COVID-19 vaccine on Monday.
Pfizer chief executive Albert Bourla hailed the approval request, describing it as another key milestone in its efforts to alleviate the health crisis, together with BioNTech.
Their vaccine has been found to be 95 per cent effective against COVID-19 in clinical tests.
Like Moderna, BioNTech and Pfizer have also applied to the U.S. Food and Drug Administration (FDA) for emergency approval.
Support PREMIUM TIMES' journalism of integrity and credibility
Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.
For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.
By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.
TEXT AD: To advertise here . Call Willie +2347088095401...